One To Watch

Vaxcyte

A clinical-stage vaccine company headquartered in San Carlos, California. Operations are centered on research, development and manufacturing scale-up for bacterial vaccines, with clinical programs run through external trial networks.

Founding and History

Vaxcyte was incorporated in 2013 (originally SutroVax) and rebranded as Vaxcyte in 2020. The company is publicly traded on Nasdaq under ticker PCVX. Its strategy has been to build a bacterial vaccine portfolio anchored by next-generation pneumococcal conjugate vaccines with expanded serotype coverage versus marketed PCVs.

Therapy Areas and Focus

Vaxcyte focuses on vaccines to prevent bacterial infectious diseases. The lead franchise targets pneumococcal disease, with additional programs aimed at other high-burden bacterial pathogens where improved breadth and immunogenicity could be clinically and commercially meaningful.

Technology Platforms and Modalities

Vaxcyte’s platform is designed to engineer “high-fidelity” conjugate vaccines, using cell-free protein synthesis and site-specific conjugation approaches intended to improve consistency, enable broader valency, and preserve immunogenicity as serotype count increases.

Lead assets and stage (as disclosed by the company):

VAX-31 (31-valent pneumococcal conjugate vaccine): in Phase III for adults and Phase II in infants
VAX-24 (24-valent pneumococcal conjugate vaccine): earlier-generation PCV program used to inform dose/strategy for next-generation candidates and evaluated clinically in pediatric development work

Additional preclinical programs include candidates for Group A Streptococcus and Shigella

Key Personnel

Grant Pickering is Founder and Chief Executive Officer.

Strategic Partnerships

Vaxcyte’s model is primarily internally driven, with external relationships focused on clinical operations, manufacturing scale-up and supply-chain readiness. The company has also emphasized U.S.-based fill-finish capacity planning as part of commercial preparedness.

FAQ Section

Vaxcyte develops bacterial vaccines using a conjugate vaccine engineering platform intended to support higher-valency products with consistent manufacturing and strong immunogenicity. The core technical differentiators are cell-free protein synthesis and site-specific conjugation methods aimed at enabling broad-spectrum coverage.

Vaxcyte focuses on prevention of bacterial infectious diseases. Its lead programs target pneumococcal disease (including invasive pneumococcal disease and pneumococcal pneumonia), with additional pathogen programs disclosed in earlier development.

VAX-31 is the lead program, in Phase III development for adults and Phase II development for infants. Vaxcyte has also advanced VAX-24 clinically as part of its pneumococcal franchise development and learning strategy. The broader pipeline includes preclinical vaccine candidates for other bacterial pathogens.

Recent updates have centered on execution of the VAX-31 adult Phase III program (including trial initiation and dosing) and progress in the VAX-31 infant Phase II program, alongside manufacturing readiness initiatives, including planned buildout of U.S. fill-finish capability.

Vaxcyte has presented clinical immunogenicity and safety datasets from adult studies supporting advancement of VAX-31 into Phase III and informing pediatric dose selection work. The company’s current value inflection points are tied to Phase III execution in adults and maturing Phase II immunogenicity datasets in infants.

For adults, key milestones are completion of ongoing Phase III studies and associated regulatory alignment on immunogenicity endpoints and comparators typical for pneumococcal vaccines. For infants, milestones are continued Phase II readouts to support selection of dose and regimen for later-stage pediatric development.

Vaxcyte is led by a founder-CEO with prior vaccine and biotech operating experience. The leadership structure is oriented toward advancing a single lead franchise through parallel adult and pediatric development while building manufacturing and supply capabilities consistent with late-stage vaccine development requirements.

Want to Update your Company's Profile?